Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Different-dose enoxaparin for thromboembolism prevention in sepsis
ChiCTR2400082589Phase 4Not yet recruiting
- Sponsor
- People's Hospital of Jiangdu
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of enoxaparin in sepsis (2 arms), sponsored by People's Hospital of Jiangdu. Primary endpoint: Thromboembolism incidence. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
enoxaparin
03
Conditions
sepsis
Beyond the preview
Go deeper on ChiCTR2400082589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082589.